Pathalys Pharma, Inc. is focused on addressing the significant unmet needs in the management of chronic kidney disease (CKD), particularly in patients with end-stage kidney disease. The company is developing advanced therapeutics, with an initial emphasis on treating secondary hyperparathyroidism (SHPT), a condition often resulting from kidney failure and vitamin D deficiency. Pathalys has introduced upacicalcet, a novel calcimimetic designed to improve the treatment of SHPT. This drug works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor, which is crucial for regulating parathyroid hormone (PTH) levels. Upacicalcet can be administered intravenously at the end of hemodialysis sessions, potentially offering better tolerability and effectiveness in reducing PTH levels compared to existing treatments.

In addition to upacicalcet, Pathalys is committed to identifying and developing further therapeutic solutions for patients suffering from end-stage kidney disease. The company has garnered significant funding to support its mission and is actively engaged in clinical development, including pivotal trials to evaluate the efficacy of upacicalcet. By focusing on innovative treatment options, Pathalys aims to enhance the quality of life for patients with CKD and address the critical gaps in current therapeutic approaches.

United States

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of advanced therapeutics that address unmet needs in the management of late-stage chronic kidney disease (CKD). Pathalys was created in partnership with Catalys Pacific and DaVita to become a multi-asset pharmaceutical company focused on the needs of patients with end-stage renal disease

Pathalys

Company Details